Venous thromboembolism and cyproterone acetate in men with prostate cancer: A study using the General Practice Research Database

BJU International

Volumn 99, Issue 6, 2007, Pages 1398-1403

  Seaman, Helen E ^a   Langley, Stephen E M ^b   Farmer, Richard D T ^a   De Vries, Corinne S ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

Author keywords

Cyproterone acetate; General Practice Research Database; Prostate cancer; Venous thromboembolism

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; ESTRAMUSTINE PHOSPHATE; ESTROGEN; FLUTAMIDE; GONADORELIN DERIVATIVE; GOSERELIN; LEUPRORELIN; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER HORMONE THERAPY; CASE CONTROL STUDY; CLINICAL RESEARCH; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA BASE; DRUG USE; GENERAL PRACTICE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; ORCHIECTOMY; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; VENOUS THROMBOEMBOLISM; CHEMICALLY INDUCED DISORDER; COHORT ANALYSIS; HOSPITALIZATION; MIDDLE AGED; MORTALITY; PROSTATE TUMOR; RISK FACTOR; SURVIVAL; THROMBOEMBOLISM; VEIN THROMBOSIS;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; COHORT STUDIES; CYPROTERONE ACETATE; DATABASES; FAMILY PRACTICE; HUMANS; MALE; MIDDLE AGED; ORCHIECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 34447322071     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.06859.x     Document Type: Article

References (28)

1. British National Formulary. London : British Medical Association and the Royal Pharmaceutical Society of Great Britain, September 2004
2. Moffat LE. Comparison of Zoladex, diethylstilbestrol and cyproterone acetate treatment in advanced prostate cancer. Eur Urol 1990 18 (Suppl. 3 26 7
3. Goldenberg SL, Bruchovsky N, Rennie PS, Coppin CM. The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma. J Urol 1988 140 : 1460 5
4. Pavone-Macaluso M, de Voogt HJ, Viggiano G et al. Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group. J Urol 1986 136 : 624 31
5. de Voogt HJ, Smith PH, Pavone-Macaluso M, de Pauw M, Suciu S. Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762. J Urol 1986 135 : 303 7
6. Schroder FH, Whelan P, de Reijke TM et al. Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the 'European Organization for Research and Treatment of Cancer' (EORTC) Protocol 30892. Eur Urol 2004 45 : 457 64
7. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005 293 : 715 22
8. Blomback M, Hedlund PO, Sawe U. Changes in blood coagulation and fibrinolysis in patients on different treatment regimens for prostatic cancer. Predictors for cardiovascular complications? Thromb Res 1988 49 : 111 21
9. Falanga A. Mechanisms of hypercoagulation in malignancy and during chemotherapy. Haemostasis 1998 28 (Suppl. 3 50 60
10. Bergqvist D. Venous thromboembolism and cancer: prevention of VTE. Thromb Res 2001 102 : V209 13
11. Falanga A. Thrombosis and malignancy: an underestimated problem. Haematologica 2003 88 : 607 10
12. Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation 2003 107 (23 Suppl. 1 I17 21
13. Rickles FR, Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb Res 2001 102 : V215 24
14. Guidelines on the management of prostate cancer. A Document for Local Expert Groups in the United Kingdom Preparing Prostate Management Policy Documents. The Royal College of Radiologists Clinical Oncology Information Network and the British Association of Urological Surgeons, 2001
15. Committee on Safety of Medicines. Hepatic reactions with cyproterone acetate (Cyprostat, Androcur). Current Problems in Pharmacovigilance 1995 21 : 1
16. Walley T, Mantgani A. The UK General Practice Research Database. Lancet 1997 350 : 1097 9
17. Van Staa T, Abenheim L. The quality of information on a UK database of primary care records: a study of hospitalizations due to hypoglycaemia and other conditions. Pharmacoepidemiol Drug Safety 1994 3 : 15 21
18. Hansell A, Hollowell J, Nichols T, McNiece R, Strachan D. Use of the General Practice Research Database (GPRD) for respiratory epidemiology: a comparison with the 4th Morbidity Survey in General Practice (MSGP4). Thorax 1999 54 : 413 9
19. Hollowell J. The General Practice Research Database: quality of morbidity data. Popul Trends 1997 87 : 36 40
20. Lawrenson R, Todd JC, Leydon GM, Williams TJ, Farmer RD. Validation of the diagnosis of venous thromboembolism in general practice database studies. Br J Clin Pharmacol 2000 49 : 591 6
21. Jick SS, Kaye JA, Vasilakis-Scaramozza C et al. Validity of the General Practice Research Database. Pharmacotherapy 2003 23 : 686 9
22. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom BMJ 1991 302 : 766 8
23. Perry J. OXMIS Problem Codes for Primary Medical Care. Oxford : OXMIS Publications, 1978
24. Chisholm J. The Read clinical classification. BMJ 1990 300 : 1467
25. Paisey RB, Kadow C, Bolton C, Hartog M, Gingell JC. Effects of cyproterone acetate and a long-acting LHRH analogue on serum lipoproteins in patients with carcinoma of the prostate. J R Soc Med 1986 79 : 210 1
26. Varenhorst E, Karlberg BE, Risberg B, Wallentin L, Wranne B. [Effects of cyproterone acetate on cardiovascular risk factors in patients with carcinoma of the prostate]. Urologe A 1981 20 : 218 22
27. Seaman HE, de Vries CS, Farmer RD. The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study. Hum Reprod 2003 18 : 522 6
28. Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet 2001 358 : 1427 9